RxDoctor Payments DataLook up a doctor →

Daniel Rakowski, MD

Nephrology · Chesapeake, VANPI 1275504029

Payments from drug & device makers

$405,270in general payments, 2019–2025

Across 555 payments — averaging $730.22 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • CSL Behring$229K
  • Boehringer Ingelheim International GmbH$104K
  • Akebia Therapeutics Inc$43K
  • Bayer$13K
  • Astrazeneca UK Limited$8K
  • AstraZeneca$2K
  • plus $6K from 27 others

What the payments were for

  • Food & beverage$6,89192%
  • Education$6128%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$405,270 in reported general payments places this provider in the 95th percentile of 298 nephrology providers in Virginia.

See all nephrology providers in Virginia

Medicare billing

Part B allowed, 2024
$306,183
Medicare patients
645
Services billed
2,175

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
KerendiaFinerenone25$43,261
FarxigaDapagliflozin Propanediol36$36,888
Tacrolimus24$6,263
Sevelamer Carbonate29$3,827
Mycophenolic AcidMycophenolate Sodium17$2,354
Calcium Acetate32$2,018
Nifedipine ErNifedipine32$1,685
Bumetanide19$1,206
Midodrine Hcl11$1,067
Allopurinol89$1,008
Metolazone21$916
Calcitriol44$846
Furosemide135$839
Carvedilol67$697
Potassium Chloride30$555

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
BayerKerendia$12,826$43,26125 claims
AstraZenecaFarxiga$1,836$36,88836 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 298 nephrology providers in Virginia.

Other nephrology in Chesapeake

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →